Lupus Nephritis; Pathogenesis and Treatment Update Review

Elmukhtar Habas, Fahim Yousaf Khan


Lupus nephritis (LN) is a serious complication of systemic lupus erythematosus (SLE). LN is a leading cause of morbidity and mortality in SLE patients. LN presents with various symptoms and signs, ranging from asymptomatic renal involvement to End-Stage Renal Failure (ESRD). The pathogenesis of LN is not clearly understood, however, there are extra and intra-renal underlying factors that have been postulated in LN pathogenesis. Renal biopsy is crucial to stage LN and to rule out other causes. Histopathological studies have shown six different types of LN. Knowing the histopathological lesion, chronicity and the disease activity are essential to plan the LN treatment and to predict the outcome. There are different regimens for treating LN. In this review, LN pathogenesis and new advances in treatment will be briefly reviewed.


Lupus nephritis, dsDNA, immune complexes, SLE, LN, MMF, cyclophosphamide

Full Text:



Jorge A, Wallace ZS, Lu N, Zhang Y, Choi HK. Renal transplantation and survival among patients with lupus nephritis. Ann Intern Med. 2019;170(4):240–7.

Faurschou M, Dreyer L, Kamper AL, Starklint H JS. Long-term mortality and renal outcome in a cohort of 100 patients with lupus nephritis. Arthritis Care Res. 2010;62(6):873–880.

Parikh S V., Almaani S, Brodsky S, Rovin BH. Update on Lupus Nephritis: Core Curriculum 2020. Vol. 76, American Journal of Kidney Diseases. 2020.

Gergianaki I, Fanouriakis A, Repa A, Tzanakakis M, Adamichou C PA. Epidemiology and burden of systemic lupus erythematosus in a Southern European population: data from the community-based lupus registry of Crete, GreeceAnn Rheum Dis. Ann Rheum Dis. 2017;76(12):1992–2000.

Anders HJ, Saxena R, Zhao MH, Parodis I, Salmon JE MC. Lupus nephritis. Nat Rev Dis Prim. 2020;6(1):7.

Almaani S, Meara A RB. Update on lupus nephritis. Clin J Am Soc Nephrol. 2017;12(5):825–835.

Singh S, Zhou XJ, Ahn C SR. A retrospective analysis of clinical presentation of lupus nephritis. Am J Med Sci. 2011;342(6):467–73.

Zabaleta-Lanz M, Vargas-Arenas RE, Tapanes F, Daboin I, Atahualpa Pinto J BN. Silent nephritis in systemic lupus erythematosus. Lupus. 2003;12:26–30.

Farah RI. Glomerulonephritis pattern at a Jordanian tertiary care center. Int J Nephrol. 2018;2018:1–7.

Tektonidou MG, Dasgupta A WM. Risk of end-stage renal disease in patients with lupus nephritis, 1971-2015: a systematic review and Bayesian meta-analysis. Arthritis Rheumatol. 2016;68(6):1432–1441.

Sterner RM, Hartono SP GJ. The Pathogenesis of Lupus Nephritis. J Clin Cell Immunol. 2014;5(2):205–26.

Plantinga L, Lim SS, Patzer R, McClellan W, Kramer M, Klein M, et al. Incidence of End-Stage Renal Disease among Newly Diagnosed Systemic Lupus Erythematosus Patients: The Georgia Lupus Registry. Arthritis Care Res. 2016;68(3):357–65.

De Zubiria Salgado A, Herrera-Diaz C. Lupus nephritis: An overview of recent findings. Autoimmune Dis. 2012;1(1).

Ortega L, Schultz D, Lenz O, Pardo V CG. Review: Lupus nephritis: pathologic features, epidemiology and a guide to therapeutic decisions. Lupus. 2010;19(5):557–74.

Ong C, Nicholls K BG. Ethnicity and lupus nephritis: an Australian single centre study. Intern Med J. 2011;41(3):270–278.

Ichinose K, Kitamura M, Sato S, Fujikawa K, Horai Y, Matsuoka N, Tsuboi M, Nonaka F, Shimizu T, Sumiyoshi R, Koga T, Kawashiri SY, Iwamoto N, Igawa T, Tamai M, Nakamura H, Origuchi T, Nishino T KA. Comparison of complete renal response and mortality in early- and late-onset lupus nephritis: a multicenter retrospective study of a Japanese cohort. Arthritis Res Ther. 2020;22(175):1–10.

Bhinder S, Singh A M V. Membranous (class V) renal disease in systemic lupus erythematosus may be more common than previously reported: results of a 6-year retrospective analysis. Am J Med Sci. 2010;339(3):230–1.

Mok CC, Tang SS, To CH PM. Incidence and risk factors of thromboembolism in systemic lupus erythematosus: a comparison of three ethnic groups. Arthritis Rheum. 2005;52:2774–82.

Alarcoon GS, Roseman JM, McGwin G, Uribe Jr A, Bastian HM, Fessler BJ, Baethge BA, Friedman AW RJ for the LSG. Lupus in Minority populations: Nature vs nurture. Systemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosis. Lupus. 2002;11(3):152–60.

Ugolini-Lopes MR, Santos LPS, Stagnaro C, Seguro LPC, Mosca M BE. Late onset biopsy-proven lupus nephritis without other associated autoimmune diseases: severity and long-term outcome. Lupus. 2019;28(1):123–128.

O’Flynn J, Flierman R, van der Pol P, Rops A, Satchell SC, Mathieson PW, van Kooten C, van der Vlag J, Berden JH DM. Nucleosomes and C1q bound to glomerular endothelial cells serve as targets for autoantibodies and determine complement activation. Mol Immunol. 2011;49(12):75–83.

Yin Y, Wu X, Shan G ZX. Diagnostic value of serum anti-C1q antibodies in patients with lupus nephritis: a meta-analysis. Lupus. 2012;21(10):1088–97.

Lech M AH. The pathogenesis of lupus nephritis. J Am Soc Nephrol. 2013;24(9):1357–66.

D’Andrea DM, Coupaye-Gerard B, Kleyman TR, Foster MH MM. Lupus autoantibodies interact directly with distinct glomerular and vascular cell surface antigens. Kidney Int. 1996;49:1214–21.

Kalaaji M, Fenton KA, Mortensen ES, Olsen R, Sturfelt G, Alm P RO. Glomerular apoptotic nucleosomes are central target structures for nephritogenic antibodies in human SLE nephritis. Kidney Int. 2007;71(7):664–72.

Du H, Chen M, Zhang Y, Zhao MH WH. Cross-reaction of anti-DNA autoantibodies with membrane proteins of human glomerular mesangial cells in sera from patients with lupus nephritis. Clin Exp Immunol. 2006;145(1):21–7.

Belmont HM, Abramson SB LJ. Pathology and pathogenesis of vascular injury in systemic lupus erythematosus. Interactions of inflammatory cells and activated endothelium. Arthritis Rheum. 1996;39:9–22.

Vielhauer V, Anders HJ SD. Chemokines and chemokine receptors as therapeutic targets in lupus nephritis. Semin Nephrol. 2007;27:81–97.

Delmas Y, Viallard JF, Solanilla A, Villeneuve J, Pasquet JM, Belloc F, Dubus I, Déchanet-Merville J, Merville P, Blanco P, Pellegrin JL, Nurden AT, Combe C RJ. Activation of mesangial cells by platelets in systemic lupus erythematosus via a CD154-dependent induction of CD40. Kidney Int. 2005;68(5):2068–78.

Munroe ME JJ. Genetics of Lupus Nephritis. Clinical Implications. Semin Nephrol. 2015;35:396–409.

Revisited RPSWG on the C of LNT classification of glomerulonephritis in systemic lupus erythematosus. Weening JJ, D’Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, Balow JE, Bruijn JA, Cook T, Ferrario F, Fogo AB, Ginzler EM, Hebert L, Hill G, Hill P, Jennette JC, Kong NC, Lesavre P, Lockshin M, Looi LM, Makino H, Moura LA, Nagata M; International . Kidney Int. 2004;65(2):521–530.

Karassa FB, Trikalinos TA IJ. FcgammaRIIa-SLE Meta-Analysis Investigators. Role of the Fc gamma receptor IIa polymorphism in susceptibility to systemic lupus erythematosus and lupus nephritis: a meta-analysis. Arthritis Rheum. 2002;46:1563–671.

Aitman TJ, Dong R, Vyse TJ, Norsworthy PJ, Johnson MD, Smith J, Mangion J, Roberton-Lowe C, Marshall AJ, Petretto E, Hodges MD, Bhangal G, Patel SG, Sheehan-Rooney K, Duda M, Cook PR, Evans DJ, Domin J, Flint J, Boyle JJ, Pusey CD CH. . Copy number polymorphism in Fcgr3 predisposes to glomerulonephritis in rats and humans. Nature. 2006;439(7078):851–5.

Freedman BI, Langefeld CD, Andringa KK, Croker JA, Williams AH, Garner NE, Birmingham DJ, Hebert LA, Hicks PJ, Segal MS, Edberg JC, Brown EE, Alarcón GS, Costenbader KH, Comeau ME, Criswell LA, Harley JB, James JA, Kamen DL, Lim SS, Merrill JT, Sivils KL, KR. Lupus Nephritis–End‐Stage Renal Disease Consortium. End-stage renal disease in African Americans with lupus nephritis is associated with APOL1. 2014;66(2):390–6.

Migliorini A AH. A novel pathogenetic concept-antiviral immunity in lupus nephritis. Nat Rev Nephrol. 2012;8:183–189.

Munoz LE, Lauber K, Schiller M, Manfredi AA HM. The role of defective clearance of apoptotic cells in systemic autoimmunity. Nat Rev Rheumatol. 2010;6:280–289.

Bosch X. Systemic lupus erythematosus and the neutrophil. N Engl J Med. 2011;365:758–60.

Theofilopoulos AN, Baccala R, Beutler B KD. Type I interferons (alpha/beta) in immunity and autoimmunity. Annu Rev Immunol. 2005;23:307–336.

Caricchio R, McPhie L CPL. Ultraviolet B radiation-induced cell death: Critical role of ultraviolet dose in inflammation and lupus autoantigen redistribution. J Immunol. 2003;171:5778–5786.

Hughes GC. Progesterone and autoimmune disease. Autoimmun Rev. 2012;11:502–514.

Tojo T FG. Lupus nephritis: Varying complement-fixing properties of immunoglobulin G antibodies to antigens of cell nuclei. Science (80- ). 1968;161:904–906.

Jacob N SW. Autoantibody-dependent and autoantibody-independent roles for B cells in systemic lupus erythematosus: Past, present, and future. Autoimmunity. 2010;43:84–97.

Furness PN TN. Interobserver reproducibility and application of the ISN/RPS classification of lupus nephritis-a UK-wide study. Am J Surg Pathol. 2006;30:1030–5.

Markowitz GS D VD. Classification of lupus nephritis. Curr Opin Nephrol Hypertens. 2009;18:220–5.

Mortensen ES RO. Nephritogenic potential of anti-DNA antibodies against necrotic nucleosome. J Am Soc Nephrol. 2009;20:696–704.

Mjelle JE, Rekvig OP, Van Der Vlag J FK. Nephritogenic antibodies bind in glomeruli through interaction with exposed chromatin fragments and not with renal cross-reactive antigens. Autoimmunity. 2011;44:373–383.

De Lema GP, Maier H, Franz TJ, Escribese M, Chilla S, Segerer S, et al. Chemokine receptor Ccr2 deficiency reduces renal disease and prolongs survival in MRL/lpr lupus-prone mice. J Am Soc Nephrol. 2005;16(12):3592–3601.

Bao L, Haas M QR. Complement factor H deficiency accelerates development of lupus nephritis. J Am Soc Nephrol. 2011;22:285–295.

Triantafyllopoulou A, Franzke CW, Seshan SV, Perino G, Kalliolias GD, Ramanujam M, van Rooijen N, Davidson A IL. Proliferative lesions and metalloproteinase activity in murine lupus nephritis mediated by type I interferons and macrophages. Proc Natl Acad Sci USA. 2010;107:3012–3017.

Fairhurst AM, Xie C, Fu Y, Wang A, Boudreaux C, Zhou XJ, Cibotti R, Coyle A, Connolly JE, Wakeland EK MC. Type I interferons produced by resident renal cells may promote end-organ disease in autoantibody-mediated glomerulonephritis. J Immunol. 2009;183(10):6831–8.

Teichmann LL, OlsML, KashgarianM, Reizis B, Kaplan DH SM. Dendritic cells in lupus are not required for activation of T and B cells but promote their expansion, resulting in tissue damage. Immunity. 2010;33:967–978.

Kulkarni O, Pawar RD, Purschke W, Eulberg D, Selve N, Buchner K, Ninichuk V, Segerer S, Vielhauer V, Klussmann S AH-J. Spiegelmer inhibition of CCL2/MCP-1 ameliorates lupus nephritis in MRL-(Fas)lpr mice. J Am Soc Nephrol. 2007;18:2350–2358.

Deban L, Russo RC, Sironi M, Moalli F, Scanziani M, Zambelli V, Cuccovillo I, Bastone A, Gobbi M, Valentino S, Doni A, Garlanda C, Danese S, Salvatori G, Sassano M, Evangelista V, Rossi B, Zenaro E, Constantin G, Laudanna C, Bottazzi B MA. Regulation of leukocyte recruitment by the long pentraxin PTX3. Nat Immunol. 2010;11(4):328–34.

Smeets B, Kuppe C, Sicking EM, Fuss A, Jirak P, Van Kuppevelt TH, et al. Parietal epithelial cells participate in the formation of sclerotic lesions in focal segmental glomerulosclerosis. J Am Soc Nephrol. 2011;22(7):1262–74.

Gasparotto M, Gatto M, Binda V, Doria A, Moroni G. Lupus nephritis: clinical presentations and outcomes in the 21st century. Rheumatology (Oxford). 2020;59(5):39–51.

Moroni G, Gallelli B, Quaglini S, Banfi G, Rivolta E, Messa P PC. Withdrawal of therapy in patients with proliferative lupus nephritis: long-term follow-up. . 2006;21(6): Nephrol Dial Transpl. 2006;21(6):1541–8.

Schwartz MM, Kawala KS, Corwin HL, Lewis EJ. The prognosis of segmental glomerulonephritis in systemic lupus erythematosus. Kidney Int. 1987;32(2):274–9.

Hervier B, Hamidou M, Haroche J, Durant C, Mathian A AZ. Systemic lupus erythematosus associated with ANCA-associated vasculitis: an overlapping syndrome? Rheumatol Int. 2012;32(10):3285–90.

Rovin BH, Caster DJ, Cattran DC, Gibson KL, Hogan JJ, Moeller MJ, et al. Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2019;95(2):281–95.

Korbet SM, Schwartz MM, Evans J, Lewis EJ. Severe lupus nephritis: Racial differences in presentation and outcome. J Am Soc Nephrol. 2007;18(1):244–54.

Dooley MA GE. Newer therapeutic approaches for systemic lupus erythematosus: immunosuppressive agents. Rheum Dis Clin North Am. 2006;32(1):91–102.

Lightstone L HM. Lupus Nephritis and Pregnancy: Concerns and Management. Semin Nephrol. 2017;37(4):347–53.

Moroni G, Doria A, Giglio E, Tani C, Zen M, Strigini F, Zaina B, Tincani A, de Liso F, Matinato C, Grossi C, Gatto M, Castellana P, Limardo M, Meroni PL, Messa P, Ravani P MM. Fetal outcome and recommendations of pregnancies in lupus nephritis in the 21st century. A prospective multicenter study. J Autoimmun. 2016;74:6–12.

Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J MJ. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med. 2005;353(21):2219–28.

Somers EC, Marder W, Christman GM, Ognenovski V MW. Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus. Arthritis Rheum. 2005;52(9):2761–7.

Dooley MA, Jayne D, Ginzler EM, Isenberg D, Olsen NJ, Wofsy D, Eitner F, Appel GB, Contreras G, Lisk L SNAG. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med. 2011;365(20):1886–95.

Tamirou F, D’Cruz D, Sangle S, Remy P, Vasconcelos C, Fiehn C, Ayala Guttierez Mdel M, Gilboe IM, Tektonidou M, Blockmans D, Ravelingien I, le Guern V, Depresseux G, Guillevin L, Cervera R HFMNTG. Long-term follow-up of the MAINTAIN Nephritis Trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis. Ann Rheum Dis2. 16AD;75(3):526–31.

Habas A, Khammaj A R. Hematologic Side Effects of Azathioprine and Mycophenolate in Kidney Transplantation. Transplant Proc. 2011;43(2):504–6.

Mok CC, Ying KY, Yim CW, Ng WL WW. Very long-term outcome of pure lupus membranous nephropathy treated with glucocorticoid and azathioprine. Lupus. 2009;18(12):1091–5.

Cassia M, Alberici F, Gallieni M JD. Lupus nephritis and B-cell targeting therapy. Expert Rev Clin Immunol. 2017;13(10):951–62.

Zhong Z, Li H, Zhong H ZT. Clinical efficacy and safety of rituximab in lupus nephritis. Drug Des Devel Ther. 2019;13:845–56.

Condon MB, Ashby D, Pepper RJ, Cook HT, Levy JB, Griffith M, et al. Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis. 2013;72(8):1280–6.

Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010;62(1):222–33.

Rovin BH, Furie R, Latinis K, Looney RJ, Fervenza FC, Sanchez-Guerrero J, Maciuca R, Zhang D, Garg JP, Brunetta P AGLIG. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 2012;64(4):1215–26.

Haarhaus ML, Svenungsson E GI. Ofatumumab treatment in lupus nephritis patients.. ; (): Clin Kidney J. 2016;9(4):552–5.

Rovin BH, Solomons N, Pendergraft WF 3rd, Dooley MA, Tumlin J, Romero-Diaz J, Lysenko L, Navarra SV HRA-LSG. A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis. Kidney Int. 2019;95(1):219–31.

Frelick M. Dawn of New Lupus Nephritis Treatment After AURORA Trial. Medscape Medical News.27,2020. Available at

Mok CC JD. Pro: The use of calcineurin inhibitors in the treatment of lupus nephritis. Nephrol Dial Transpl. 2016;31:1572–6.

Dall’Era M, Chakravarty E, Wallace D, Genovese M, Weisman M, Kavanaugh A, Kalunian K, Dhar P, Vincent E, Pena-Rossi C WD. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum. 2007;56(12):4142–50.

Furie R. Abetimus sodium (riquent) for the prevention of nephritic flares in patients with systemic lupus erythematosus. Rheum Dis Clin North Am. 2006;32(1):149–56.

Kirou KA, Salmon JE CM. Soluble mediators as therapeutic targets in systemic lupus erythematosus: cytokines, immunoglobulin receptors, and the complement system. Rheum Dis Clin North Am. 2006;32(1):103–19.

Furie R, Rovin BH, Houssiau F, Malvar A, Teng YKO, Contreras G, Amoura Z, Yu X, Mok CC, Santiago MB, Saxena A, Green Y, Ji B, Kleoudis C, Burriss SW, Barnett C R DA. Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis. Engl J Med. 2020;383(1):1117–28.

Coplon NS, Diskin CJ, Petersen J SR. The long-term clinical course of systemic lupus erythematosus in end-stage renal disease. N Engl J Med. 1983;308(4):186–90.

Mojcik CF KJ. End-stage renal disease and systemic lupus erythematosus. Am J Med. 1996;101:100–7.

Okano K, Yumura W, Nitta K, Uchida K, Ohnuki T, Kawashima A NH. Analysis of lupus activity in end-stage renal disease treated by hemodialysis. Intern Med. 2001;40(7):598–602.

Goo YS, Park HC, Choi HY, Kim BS, Park YB, Lee SK K, SW, Kim SI, Kim YS, Park KI, Lee HY, Han DS CK. The evolution of lupus activity among patients with end-stage renal disease secondary to lupus nephritis. Yonsei Med J. 2004;45:199–206.

Huang JW, Hung KY, Yen CJ, Wu KD TT. Systemic lupus erythematosus and peritoneal dialysis: outcomes and infectious. Perit Dial Int. 2001;21:143–147.

Albuquerque BC, Salles VB, Tajra RD de P, Rodrigues CEM. Outcome and Prognosis of Patients With Lupus Nephritis Submitted to Renal Transplantation. Sci Rep [Internet]. 2019;9(1):1–8. Available from:

Bertsias GK, Tektonidou M, Amoura Z, Aringer M, Bajema I, Berden JHM, et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771–82.



  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Open Science Journal (OSJ) is multidisciplinary Open Access journal. We accept scientifically rigorous research, regardless of novelty. OSJ broad scope provides a platform to publish original research in all areas of sciences, including interdisciplinary and replication studies as well as negative results.